HomeCompareARNA vs EQR

ARNA vs EQR: Dividend Comparison 2026

ARNA yields 2.00% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EQR wins by $17.9K in total portfolio value
10 years
ARNA
ARNA
● Live price
2.00%
Share price
$99.99
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.6K
Annual income
$227.64
Full ARNA calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — ARNA vs EQR

📍 EQR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodARNAEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ARNA + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ARNA pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ARNA
Annual income on $10K today (after 15% tax)
$170.02/yr
After 10yr DRIP, annual income (after tax)
$193.49/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, EQR beats the other by $3,053.17/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ARNA + EQR for your $10,000?

ARNA: 50%EQR: 50%
100% EQR50/50100% ARNA
Portfolio after 10yr
$31.5K
Annual income
$2,023.62/yr
Blended yield
6.42%
📊

Analyst Conviction Gap

Where Wall Street is split right now

ARNA
Analyst Ratings
14
Buy
9
Hold
Consensus: Buy
Price Target
$94.00
-6.0% upside vs current
Range: $90.00 — $100.00
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ARNA buys
0
EQR buys
0
No recent congressional trades found for ARNA or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricARNAEQR
Forward yield2.00%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$22.6K$40.5K
Annual income after 10y$227.64$3,819.61
Total dividends collected$2.1K$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold
Analyst price target$94.00$70.35

Year-by-year: ARNA vs EQR ($10,000, DRIP)

YearARNA PortfolioARNA Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$10,900$200.02$11,248$547.57$348.00EQR
2$11,867$203.76$12,701$666.53$834.00EQR
3$12,905$207.32$14,405$814.59$1.5KEQR
4$14,019$210.70$16,413$999.84$2.4KEQR
5$15,214$213.92$18,795$1,232.92$3.6KEQR
6$16,496$216.97$21,639$1,527.95$5.1KEQR
7$17,871$219.86$25,057$1,903.80$7.2KEQR
8$19,344$222.60$29,197$2,385.87$9.9KEQR
9$20,923$225.19$34,250$3,008.70$13.3KEQR
10$22,616$227.64$40,467$3,819.61$17.9KEQR

ARNA vs EQR: Complete Analysis 2026

ARNAStock

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.

Full ARNA Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this ARNA vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ARNA vs SCHDARNA vs JEPIARNA vs OARNA vs KOARNA vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.